Skip to content

Lisdexamfetamine

  • Prescription medicine
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Lisdexamfetamine does in the body

1) ]. 2) ] .

Lisdexamfetamine is a prodrug of dextroamphetamine. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD and BED is not known.

Why people take it. Lisdexamfetamine dimesylate capsules are indicated for the treatment of: • Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1) ]. • Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies (14.2) ] .

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · SJT761GEGS · read 2026-08-29

  • Its recorded molecular formula is C17H33N3O7S2, weighing 455.60.

    US prescribing information · efbde0f6-b848-4664-b741-c6c630e66108 · read 2026-08-30

Where each sentence above came from

The use the label states, quoted from it. No plain-language version of this sentence has been written.

The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.

No statement of the main limit is recorded.

The four opening statements run to 83 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Stand-in result

A stand-in result is a number measured because the real result takes too long.

A picture of it, and where the picture fails

It is like judging a journey by the speedometer rather than by arriving.

Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.

What people get wrong. A stand-in result is often reported as the result itself.

A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.

Enzyme

An enzyme is a protein that speeds up one chemical change.

A picture of it, and where the picture fails

An enzyme is like a machine on a production line doing one cut.

Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.

What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.

A catalytic protein that lowers the activation energy of a specific reaction.

Receptor

A receptor is a part of a cell that a signal fits into.

A picture of it, and where the picture fails

A receptor is like a lock waiting for one key.

Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.

What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.

A protein that binds a specific ligand and converts that binding into a cellular response.

Pathway

A pathway is a chain of steps inside a cell, each one setting off the next.

A picture of it, and where the picture fails

A pathway is like a row of dominoes.

Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.

What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.

An ordered series of molecular interactions producing a defined cellular change.

What happened in peopleRead from sources, not yet reviewed

What was measured, goal by goal

One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.

Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.

There is no single score. A strong test result and a weak life result are different facts.

Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
GoalLife outcomeWhat a body can doHow a person feelsA test resultA step in the bodyHarmsHow longWho was studied
FocusNothing in the sources checkedNo registered study lists a life outcome for this goal.Nothing in the sources checkedNo registered study lists a performance measure for this goal.Nothing in the sources checkedNo registered study lists a symptom measure for this goal.Nothing in the sources checkedNo registered study lists a test result for this goal.Nothing in the sources checkedNo registered study lists a body-step measure for this goal.Not recordedHarms were not a registered measure for this goal.Not recordedNo finished study window is recorded.Waiting for a reviewerWho was studied is listed further down the page.
MoodNothing in the sources checkedNo registered study lists a life outcome for this goal.Nothing in the sources checkedNo registered study lists a performance measure for this goal.Waiting for a reviewer2 registered symptom measure.Nothing in the sources checkedNo registered study lists a test result for this goal.Nothing in the sources checkedNo registered study lists a body-step measure for this goal.Not recordedHarms were not a registered measure for this goal.Not recordedNo finished study window is recorded.Waiting for a reviewerWho was studied is listed further down the page.
SleepNothing in the sources checkedNo registered study lists a life outcome for this goal.Nothing in the sources checkedNo registered study lists a performance measure for this goal.Nothing in the sources checkedNo registered study lists a symptom measure for this goal.Nothing in the sources checkedNo registered study lists a test result for this goal.Nothing in the sources checkedNo registered study lists a body-step measure for this goal.Not recordedHarms were not a registered measure for this goal.Not recordedNo finished study window is recorded.Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Focus
brown attention deficit disorder scale; attention deficit hyperactivity disorder symptomatology; working memory
Mood
montgomery asberg depression rating scale; madrs
Sleep
latency to persistent sleep as measured by polysomnography

Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.

What each mark on this table means
Nothing in the sources checked
No registered study lists a life outcome for this goal.
Not recorded
Harms were not a registered measure for this goal.
Waiting for a reviewer
Who was studied is listed further down the page.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Columbia-Suicide Severity Rating Scale (C-SSRS)

The study did not show it

Who was studied
NCT01436175
How many people
1570
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • Europe PMC · a recorded source, not a stored snapshot
  • CMS National Average Drug Acquisition Cost · a recorded source, not a stored snapshot

Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks

The study did not show it

Who was studied
NCT01436149
How many people
1262
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • Europe PMC · a recorded source, not a stored snapshot
  • CMS National Average Drug Acquisition Cost · a recorded source, not a stored snapshot

Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)

The study did not show it

Who was studied
NCT01435759
How many people
1197
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • Europe PMC · a recorded source, not a stored snapshot
  • CMS National Average Drug Acquisition Cost · a recorded source, not a stored snapshot

Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks

The study did not show it

Who was studied
NCT01436162
How many people
1105
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • Europe PMC · a recorded source, not a stored snapshot
  • CMS National Average Drug Acquisition Cost · a recorded source, not a stored snapshot

Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase B

The study did not show it

Who was studied
NCT01074294
How many people
740
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • Europe PMC · a recorded source, not a stored snapshot
  • CMS National Average Drug Acquisition Cost · a recorded source, not a stored snapshot

Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) as a Measure of Safety

The study did not show it

Who was studied
NCT01657019
How many people
604
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • Europe PMC · a recorded source, not a stored snapshot
  • CMS National Average Drug Acquisition Cost · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What happened in peopleRead from sources, not yet reviewed

How close this is to real life

The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.

  1. Living longer, or avoiding a major event No evidence recorded. Death, a heart attack, a stroke, a hospital stay.No registered study measures this.
  2. What a body can do day to day No evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
  3. Measured performance No evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
  4. Symptoms and quality of life Evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.5 registered measures of this kind.
  5. A number that stands in for health Evidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.3 registered measures of this kind.
  6. A step measured inside a person Evidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
  7. Animals Evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Dog. A result in animals says what to test next. It does not say what happens in people.
  8. Cells in a dish No evidence recorded. Cells or chemistry on a bench, far from a whole body.No cell or bench record is stored.
  9. A guess from software No evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.

Higher on these steps means closer to something a person would feel. It does not mean better done.

What it would be like to takeRead from sources, not yet reviewed

Felt, measured, or meaningful

Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.

Felt

Things a person could notice without a test.

  • dichotomized clinical global impression effectiveness scale
  • montgomery asberg depression rating scale
  • madrs
  • behavior rating inventory of executive function adult
  • clinical global impression improvement scale

Measured

Things only a test, a scale or a device shows.

  • maximum plasma concentration of guanfacine
  • time of maximum plasma concentration of guanfacine
  • time of plasma half life of guanfacine

Meaningful

Things that change how a life goes, not only a number.

No registered study measured anything of this kind.

A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.

Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.

Measured, but not felt. A number moves. The person notices nothing. Both can be true.

Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.

Matters, but takes years. The result that counts may take longer than anyone would keep watching.

Names that fit none of the three (32)
  • pharmacodynamic parameters
  • effects of adhd medication versus placebo on cotinine levels
  • latency to persistent sleep as measured by polysomnography
  • cmax of d amphetamine
  • auc of d amphetamine
  • tmax of d amphetamine
  • t 1/2 of d amphetamine
  • maintenance of wakefulness test
  • time to first response
  • metabolic parameters
  • brown attention deficit disorder scale
  • symbol digit modalities test
  • columbia suicide severity rating scale
  • adhd rating scale
  • badds
  • snap iv teacher and parent rating scale
  • p sec
  • attention deficit hyperactivity disorder symptomatology
  • maximum effect on drug liking visual analog scale
  • working memory

These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.

What it would be like to takeRead from sources, not yet reviewed

How long anything takes

Nine different lengths of time that get confused with each other. None of them is worked out from another.

  1. Before anything is noticed. RNAWiki does not store this separately, and never works it out from another figure on this page.

  2. Before a test result moves. RNAWiki does not store this separately, and never works it out from another figure on this page.

  3. Before performance moves. RNAWiki does not store this separately, and never works it out from another figure on this page.

  4. How long the result was watched. No finished study window is recorded for a study that tested this substance.

  5. How long people took it. How long people actually took it is not stored. The study window is not the same thing.

  6. How long people were followed. Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.

  7. How fast the body clears it. 8.6 to 9.5 hours hours

    Read from the label, which states: “The plasma elimination half-life of dextroamphetamine was approximately 8.6 to 9.5 hours in pediatric patients 6 to 12 years and 10 to 11.3 hours in healthy adults.”

  8. How long effects linger. RNAWiki does not store this separately, and never works it out from another figure on this page.

  9. Beyond the studies. Nothing is recorded about the long term.

    The longest finished study sets the edge of what anyone measured.

A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

No description of who was studied is recorded.

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “The safety and effectiveness of lisdexamfetamine dimesylate have not been established in pediatric patients below the age of 6 years.”

    US prescribing information · efbde0f6-b848-4664-b741-c6c630e66108 · read 2026-08-30

  • On older people, the label states: “Clinical studies of lisdexamfetamine dimesylate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.”

    US prescribing information · efbde0f6-b848-4664-b741-c6c630e66108 · read 2026-08-30

  • On people who are pregnant, the label states: “Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications during pregnancy.”

    US prescribing information · efbde0f6-b848-4664-b741-c6c630e66108 · read 2026-08-30

  • On people who are breastfeeding, the label states: “Risk Summary Lisdexamfetamine is a pro-drug of dextroamphetamine.”

    US prescribing information · efbde0f6-b848-4664-b741-c6c630e66108 · read 2026-08-30

  • On people with reduced kidney function, the label states: “Due to reduced clearance in patients with severe renal impairment (GFR 15 to < 30 mL/min/1.73 m 2 ), the maximum dose should not exceed 50 mg/day.”

    US prescribing information · efbde0f6-b848-4664-b741-c6c630e66108 · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied for a different goal

The studies measured something else entirely.

On this record: Some registered studies measured things that match no goal on this page.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No form or route is recorded.

No source is stored against this line.

Who oversees it

Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Suppression classes recorded: S2, S6.

No source is stored against this line.

What is in the pack

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing is recorded about product quality.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Reports sent to a regulator

  • These are reports people sent to a regulator. They do not show the medicine caused the reaction.
  • Nobody counted how many people took the medicine and reported nothing.
  • The same event can be reported more than once, and many reports are incomplete.
  • News coverage, lawsuits and new warnings change how often people report.
  • A count is not a rate and not a risk.

Lisdexamfetamine appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 2040 reaction mentions were counted. One report can name several reactions.

The recorded terms (10)
  • disturbance in attention — 279 reaction mentions
  • anxiety — 275 reaction mentions
  • insomnia — 257 reaction mentions
  • decreased appetite — 217 reaction mentions
  • aggression — 186 reaction mentions
  • suicidal ideation — 186 reaction mentions
  • feeling abnormal — 183 reaction mentions
  • irritability — 155 reaction mentions
  • somnolence — 151 reaction mentions
  • wrong technique in product usage process — 151 reaction mentions
  • open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

The exact form studied is not recorded.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 3 published labels name it as an active ingredient. 3 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · c11cb3b6-3dff-477b-a249-b4c3118edc5f · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · c11cb3b6-3dff-477b-a249-b4c3118edc5f · read 2026-08-29

  • Lisdexamfetamine Dimesylate is oral at 3 DOSAGE FORMS AND STRENGTHS Lisdexamfetamine Dimesylate Capsules are available containing 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg or 70 mg of lisdexamfetamine dimesylate. • The 10 mg capsules are hard-shell gelatin ca…, recorded as fda label in effect 2026-05-22 in the United States.

    US prescribing information · efbde0f6-b848-4664-b741-c6c630e66108 · read 2026-08-30

  • Recorded price in US: 2.59686–4.3927 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 152 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..

    Recorded source · 2026-08-26 · read 2026-08-28

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.

Questions worth asking

  • Which of the trials of Lisdexamfetamine studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Lisdexamfetamine are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

How many documents were read

  • 3 documents were read for this substance.

    RNAWiki source record

  • 3 of them state the same halfLife, and they agree.

    RNAWiki source record

  • 3 of them state the same tMax, and they agree.

    RNAWiki source record

Where else this substance is registered

FDA substance identifier (UNII)
SJT761GEGS

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Quoted from a stored source.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Passed

    Safety mode resolved

    Suppression classes recorded: S2, S6.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

6 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • The path through the body — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • How this medicine reached us — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (11)

What did Lisdexamfetamine's largest trial (430000 people) and its longest (13 years) measure?


430000 people in Lisdexamfetamine's largest registered study, 13 years in its longest registered window, measuring Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC. ClinicalTrials.gov · 2026-09-01

33 phase4, 27 phase3, 20 phase2, 14 phase1, 11 na, 7 na or unstated, 1 early phase1; NCT02210728; 2018-10; no ageing endpoint recorded. Last human test completed 2026, NCT05416125.

Interpretation These counts include studies where Lisdexamfetamine was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.

Show the evidence
  • phase4
    33
  • phase3
    27
  • phase2
    20
  • phase1
    14
  • na
    11
  • na or unstated
    7
2 more recorded rows
  • early phase1
    1
  • Last recorded human test NCT05416125
    2026-06-23

recorded 2026-09-01 · last checked 2026-09-04

From dog to human: where has Lisdexamfetamine shown biomarker?


dog: mechanism-only and human: biomarker (109): the rungs where Lisdexamfetamine has a recorded finding. Europe PMC and ClinicalTrials.gov · organism ladder · 2026-09-01

Interpretation Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC — the recorded outcome words.

Yeast C. elegans Drosophila Mouse Rat Dog mechanism-onlyNon-human primate Human biomarker
Show the evidence
  • dog
    mechanism-only
  • human NCT00746733
    biomarker; Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC; 109

recorded 2026-09-01 · last checked 2026-09-04

15 of Lisdexamfetamine's trials stopped: safety, accrual/recruitment, funding/business, other?


safety (5), accrual/recruitment (7), funding/business (1) and other (2): Lisdexamfetamine's stop wording, clustered. ClinicalTrials.gov · 2026-09-01

"The study was stopped by the sponsor based on a non-safety related business priority decision."; 15 of 109 registered studies

Show the evidence

Trial

  • NCT00776555
    terminated; "The study was stopped by the sponsor based on a non-safety related business priority decision."
  • NCT01000064
    terminated; "unable to meet recruitment goals"
  • NCT01051440
    terminated; "Slow enrollment"
  • NCT01093963
    terminated; "Enrollment goals not met"
  • NCT01131559
    terminated; "Sponsor halted study."
  • NCT01274221
    withdrawn; "Cancellation was not safety related but a shift in study priorities for Shire."
9 further recorded trials
  • NCT01490216
    terminated; "Low enrollment"
  • NCT01738698
    terminated; "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized."
  • NCT01760993
    terminated; "Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized."
  • NCT01986764
    withdrawn; "Funding was not obtained for this study and no participants were enrolled."
  • NCT01986777
    withdrawn; "Funding not obtained"
  • NCT02170298
    terminated; "Lack of enrollment"
  • NCT02259517
    terminated; "Recruitment/enrollment ended early due to the COVID-19 pandemic"
  • NCT03397446
    terminated; "Loss of resources due to COVID-19 resulted in insufficient funds to complete the trial as planned. However, sufficient data was collected to fulfill the aims of the trial. Discontinuation is not related to the drug, its use, or adverse…"
  • NCT04181957
    terminated; "COVID-19"

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Lisdexamfetamine used SPD489 20 mg — over how long?


studies of Lisdexamfetamine used the recorded amount. ClinicalTrials.gov · 2026-09-01

12 recorded entries; human; also "SPD489 20 mg", "SPD489 50 mg", "SPD489 70 mg"

Show the evidence

human

  • NCT01096680
    SPD489 20 mg
  • NCT01096680
    SPD489 50 mg
  • NCT01096680
    SPD489 70 mg
  • NCT01435759
    Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg
  • NCT01435759
    Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg
  • NCT01435759
    Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
6 more recorded rows
  • human NCT01435759
    Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg
  • human NCT01738698
    SPD489 40mg
  • human NCT01738698
    SPD489 100mg
  • human NCT01738698
    SPD489 160mg
  • human NCT02144415
    lisdexamfetamine 150 mg
  • human NCT03446885
    Lisdexamfetamine Dimesylate 40 MG

recorded 2026-09-01 · last checked 2026-09-04

Lisdexamfetamine's half-life is 8.6 to 9.5 hours — which schedules were studied?


8.6 to 9.5 hours, the half-life Lisdexamfetamine's label states. openfda-label · c11cb3b6-3dff-477b-a249-b4c3118edc5f · 2026-08-30

Show the evidence
  • half life
    8.6 to 9.5 hours hours; The plasma elimination half-life of dextroamphetamine was approximately 8.6 to 9.5 hours in pediatric patients 6 to 12 years and 10 to 11.3 hours in healthy adults.
  • tmax
    Absorption Capsule formulation Following single-dose oral administration of lisdexamfetamine dimesylate capsule (30 mg, 50 mg, or 70 mg) in patients ages 6 to 12 years with ADHD under fasted conditions, T max of lisdexamfetamine and dextroamphetamine was reached at approximately 1 hour and 3.5 hours post dose, respectively.
  • metabolism
    Metabolism Lisdexamfetamine is converted to dextroamphetamine and l-lysine primarily in blood due to the hydrolytic activity of red blood cells after oral administration of lisdexamfetamine dimesylate.

recorded 2026-08-30 · last checked 2026-09-04

Which of adhd rating scale, adhd symptoms and attention deficit hyperactivity disorder symptomatology did Lisdexamfetamine's trials measure?


adhd rating scale, adhd symptoms and attention deficit hyperactivity disorder symptomatology lead 40 outcome terms across Lisdexamfetamine's trials. ClinicalTrials.gov · 2026-09-01

Interpretation dichotomized clinical global impression effectiveness scale, maximum plasma concentration of guanfacine, time of maximum plasma concentration of guanfacine, time of plasma half life of guanfacine, cmax of d amphetamine and auc of d amphetamine follow.

Show the evidence
  • pharmacodynamic parameters
    1
  • effects of adhd medication versus placebo on cotinine levels
    1
  • latency to persistent sleep as measured by polysomnography
    1
  • dichotomized clinical global impression effectiveness scale
    1
  • maximum plasma concentration of guanfacine
    1
  • time of maximum plasma concentration of guanfacine
    1
14 more recorded rows
  • time of plasma half life of guanfacine
    1
  • cmax of d amphetamine
    1
  • auc of d amphetamine
    1
  • tmax of d amphetamine
    1
  • t 1/2 of d amphetamine
    1
  • montgomery asberg depression rating scale
    1
  • maintenance of wakefulness test
    1
  • time to first response
    1
  • madrs
    1
  • metabolic parameters
    1
  • brown attention deficit disorder scale
    1
  • behavior rating inventory of executive function adult
    1
  • symbol digit modalities test
    1
  • columbia suicide severity rating scale
    1

recorded 2026-09-01 · last checked 2026-09-04

Which of Lisdexamfetamine's 3 ongoing trials reports first?


3 registered trials of Lisdexamfetamine are open; earliest completion 2027-08-01. ClinicalTrials.gov · 2026-09-01

Change in Behavioral Function; Change in ADHD symptom scores on the "inattention" scale of the Conners 3 questionnaire; latest 2027-12-01

Show the evidence

Trial

  • NCT03420339
    "Stimulant Effects on Disruptive Behavior"; n 10; "Change in Behavioral Function"; 2027-08-01
  • NCT05957055
    "Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes"; n 150; "Change in ADHD symptom scores on the "inattention" scale of the Conners 3 questionnaire"; 2027-12-01
  • NCT06847399
    "Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder"; n 105; "Percent initial weight loss"; 2027-12-01

recorded 2026-09-01 · last checked 2026-09-04

Which 21 trials of Lisdexamfetamine posted no result?


Posted no result
21 of 21 completed trials
Registrations
NCT00557011, NCT00556296, NCT00247572, NCT00248092, NCT00334880 and NCT00807222, and 15 more
Completion dates
oldest 2004-12; newest 2023-03-31
Show the evidence

Trial

  • NCT00557011
    2004-12
  • NCT00556296
    2005-09
  • NCT00247572
    2005-11
  • NCT00248092
    2006-05
  • NCT00334880
    2006-11
  • NCT00807222
    2008-08
14 further recorded trials
  • NCT01263548
    2012-01
  • NCT01090713
    2012-10
  • NCT02144415
    2014-07-01
  • NCT02034201
    2016-05-19
  • NCT02555150
    2017-01
  • NCT01863459
    2017-03
  • NCT02675400
    2018-08-31
  • NCT04132557
    2019-10-25
  • NCT03497169
    2020-09-28
  • NCT04152629
    2021-07-09
  • NCT02136147
    2022-06
  • NCT04577417
    2022-06-15
  • NCT04946461
    2022-06-16
  • NCT05551689
    2023-03-30

At the median, Lisdexamfetamine's trials enrolled 45 people — anything larger?


Median enrolment
45
Largest enrolment
430000
Registered trials counted
109

What do 2040 spontaneous reports say about Lisdexamfetamine — and not say?


These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.

Lisdexamfetamine appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 2040 reaction mentions were counted: disturbance in attention 279; anxiety 275; insomnia 257; decreased appetite 217. open-targets-adr · CHEMBL1201178 · 2026-06-24

Show the evidence
  • disturbance in attention
    279
  • anxiety
    275
  • insomnia
    257
  • decreased appetite
    217
  • aggression
    186
  • suicidal ideation
    186
4 more recorded rows
  • feeling abnormal
    183
  • irritability
    155
  • somnolence
    151
  • wrong technique in product usage process
    151

recorded 2026-06-24 · last checked 2026-09-04

Lisdexamfetamine and CYP2D6: shared by which compounds?


CYP2D6 appear in Lisdexamfetamine's recorded interaction sentences, 2 in all. openfda-label+europepmc · 2026-08-28

Interpretation drug_interactions

Show the evidence

CYP2D6

  • drug_interactions
    CYP2D6 Inhibitors Clinical Impact The concomitant use of lisdexamfetamine dimesylate and CYP2D6 inhibitors may increase the exposure of dextroamphetamine, the active metabolite of lisdexamfetamine dimesylate compared to the use of the drug alone and increase the risk of serotonin syndrome.
  • drug_interactions
    If serotonin syndrome occurs, discontinue lisdexamfetamine dimesylate and the CYP2D6 inhibitor [see Warnings and Precautions (5.7) and Overdosage (10 )] .

recorded 2026-08-28 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL1201178
PubChem CID
11597697
CAS number
608137-33-3
RxCUI
673579
InChIKey
VOBHXZCDAVEXEY-JSGCOSHPSA-N
Also called
LISDEXAMFETAMINE DIMESYLATE, Lisdexamfetamine dimesilate, Lisdexamfetamine dimethanesulfonate, Lisdexamphetamine dimesilate, Tyvense, ldx, Lisdexamphetamine, Lisdexanfetamina, L-lysine-dextroamphetamine, ldx-01, LISDEXAMFETAMINE [MI], LISDEXAMFETAMINE [VANDF]
Trade name
Elvanse, Elvanse adult, Vyvanse, Arynta, Vyvanse / Arynta
Japanese name
Lisdexamfetamine mesilate
Development code
NRP-104, NRP104, SPD-489, SPD489
Sources (9)

Sources

3 more sources
  • openfda-label c11cb3b6-3dff-477b-a249-b4c3118edc5f ·
  • openfda-label+europepmc K1:H645GUL8KJ ·
  • national registers US, CA ·

ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 9 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.